西肽普兰联合心理治疗抑郁症疗效评价

目的探讨西肽普兰联合心理治疗对抑郁症患者的临床疗效。方法将60例抑郁症患者随机分为两组，每组30例，两组均口服西肽普兰治疗，研究组在此基础上联合心理治疗。观察8w。于治疗前及治疗2w、4w、8w末采用汉密顿抑郁量表、临床总体印象量表评定临床疗效，副反应量表评定不良反应。出院后随访1a，统计复发率。结果治疗8w末，研究组有效率80．0％，对照组为86．7％，两组有效率比较无显著性差异（P〉0．05）。治疗2w末起，两组汉密顿抑郁量表、临床总体印象量表总分均较治疗前有显著下降（P〈0．01），研究组治疗2w末较对照组下降更显著（P〈0．05）。研究组不良反应发生率为23．33％，对照组为30．0％，程度均较轻微。随访1a末，研究组复发率为13．3％，对照组为36．7％，研究组复发率显著低于对照组（P〈0．05）。结论西肽普兰联合心理治疗对抑郁症远期疗效更显著，可有效预防复发，改善预后。

Efficacy of citalopram combined with psychotherapy in the treatment of depression

Objective To explore the efficacy of eitalopram combined with psychotherapy in treating depression. Methods Sixty depression patients were randomly divided into two groups of 30 ones each,both groups took orally eitalopram and research group was plus psychotherapy for 8 weeks. Efficacies were assessed with the Hamilton Depression Scale（HAMD） and the Clinical Global Impression（CGI） before treatment and at the end of the 2na, 4th and 8th week treatment and adverse reactions with Treatment Emergent Symptom Scale（TESS）. They were followed up for 1 year after discharge, relapse rates added up. Results At the end of the 8th week, effective rates were respectively 80.0% in the research and 86.7% in the control group,which showed no significant differenee（P〉0.05）. Since the end of the 2nd week, total scores of the HAMD and CGI of both groups lowered more significantly compared with pretreatment（P〈0.01） ; at the end of the 2nd week, those did more significantly in the research than in the control group（P〈0.05）. Incidences of adverse reactions were significantly lower in the research than in the control group（13.3% vs 36.7%,P〈0.05）） at the end of 1 year follow-up. Conclusion Citalopram combined with psychotherapy has more significant prostecdtive efficacy,can effectively prevent relapse and improve prognosis.